An HIV treatment succeeds in restoring the microbiome in advanced stages of infection

by IrsiCaixa

4 months ago
dolutegravir, gut microbiome, CD4+ cell, HIV

Compared with other antiretroviral treatments, dolutegravir leads to a more balanced microbiome, similar to that of people without HIV, with lower inflammation and reduced immune system activation

The effect of the therapeutic HIV vaccine, enhanced by a drug that unblocks the immune system

by IrsiCaixa

5 months ago
HIV, Anti-PD-1 treatments, CD8+ T cells

The treatment, known as anti-PD-1, increases both the number and functionality of vaccine-induced T cells capable of recognizing and eliminating HIV

Together for a world without HIV: progress and challenges in the fight against AIDS

by Fundació Clínic per a la Recerca Biomèdica

7 months ago
HIV, AIDS

On December 1, World AIDS Day, Clínic Barcelona highlights the importance of maintaining global efforts to control and eventually eradicate HIV — a pandemic that still affects millions of people...

IrsiCaixa participates in an $18M international project to develop a preventive HIV vaccine

by IrsiCaixa

1 year ago
follicular T cells, B cells, HIV, IL-10

Interruption of HIV treatment: a new study guides the design of future clinical trials for an HIV cure

by IrsiCaixa

1 year ago
HIV

IrsiCaixa participates in an international meta-analysis to better understand the behavior of HIV during temporary treatment interruption. The study reveals that 4% of participants keep the virus unde...

The viral reservoir, the main obstacle to eradicating HIV, is up to four times smaller in those who started treatment after 2007

by IrsiCaixa

2 years ago
Antiretroviral therapy, HIV, reduction in the viral reservoir

A study led by IrsiCaixa links the improvement of antiretroviral therapies, as well as the immediate start of treatment after diagnosis, with a reduction in the viral reservoir

AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences

by Ysios Capital

2 years ago
AELIX Therapeutics, Gilead Sciences, HIV, HTI

AELIX Therapeutics, a biopharmaceutical company backed by Ysios Capital based in Barcelona, Spain, that focuses on HIV vaccine development, today announced that Gilead Sciences, Inc. (Nasdaq: GILD), b...

More than 20 years with HIV under control without treatment: what we know about exceptional elite controllers

by IrsiCaixa

2 years ago
HIV, T cells

Less viral reservoir, a strong HIV-specific response, and defective viruses are some of the key factors that allow these individuals to control HIV, representing a great model of functional cure for t...

Reviving a depleted immune system: an unmet goal for people on HIV treatment

by IrsiCaixa

3 years ago
TIGIT, immunotherapy, HIV

IrsiCaixa describes how the cells of the immune system decrease in people with HIV who have been on treatment for 10 years, and confirm the key role of TIGIT in this loss of defenses

Reduced HIV reservoir through combination of antiretroviral therapy and the anticancer drug dasatinib

by IrsiCaixa

5 years ago
chronic myeloid leukemia, anticancer drug, antiretroviral treatment, dasatinib, HIV

A study in which IrsiCaixa has participated shows that the anticancer drug dasatinib, in combination with antiretroviral treatment, reduces the reactivation ability and the size of the viral reservoir...

Update on HIV infection and the COVID-19 pandemic

by IrsiCaixa

5 years ago
HIV, Covid19, infection

In this video you can watch the course organised by the Chair in Infectious Diseases and Immunity UVIC-UCC, directed by Dr Clotet, in which all the information related to HIV infection and the COVID-1...

Therapeutic HIV vaccine achieves an immune response that improves viral control when antiretroviral treatment is interrupted

by IrsiCaixa

5 years ago
antiretroviral treatment, Infectious Diseases, vaccine, HIV

The HTI vaccine of AELIX Therapeutics, a spin-off of HIVACAT, shows in a Phase I/IIa clinical trial that 40% of the participants who received the vaccine have better control of the virus when the trea...